• Markets
  • icon
  • Companies
AGN · ASX

Argenica Therapeutics Ltd (ASX:AGN)

AU$0.76

 0.06 (8.511%)
ASX:Live
27/05/2024 04:10:54 PM
HALO Price Momentum HALO Ords HALO MQV HALO Momentum HALO Growth +7
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

AGN Overview

AGN Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About AGN

Website

N/A

Telephone

N/A

Address

Description

Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.

AGN Price Chart

Key Stats

Market Cap

AU$88.43M

PE

9.30

EV/EBITDA

1.0

Dividends Overview

DIV Yield

1.6%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.29 - 0.77

Trade Value (12mth)

AU$15,486.00

1 week

0%

1 month

35.4%

YTD

45.71%

1 year

88.89%

All time high

1.0199999809265137

Key Fundamentals

EPS 3 yr Growth

957.700%

EBITDA Margin

N/A

Operating Cashflow

-$3m

Free Cash Flow Return

-41.30%

ROIC

-60.30%

Interest Coverage

N/A

Quick Ratio

5.10

Other Data

Shares on Issue (Fully Dilluted)

99m

HALO Sector

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AGN Announcements

Latest Announcements

Date Announcements

15 May 24

ARG-007 Reduces Effects of TBI in Preclinical Study

×

ARG-007 Reduces Effects of TBI in Preclinical Study

29 April 24

DSMB Confirms Safety of First Patients Dosed

×

DSMB Confirms Safety of First Patients Dosed

24 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

22 April 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

22 April 24

Cleansing Notice

×

Cleansing Notice

12 April 24

Argenica Successfully Completes $12.0m Placement

×

Argenica Successfully Completes $12.0m Placement

12 April 24

Proposed issue of securities - AGN

×

Proposed issue of securities - AGN

12 April 24

Proposed issue of securities - AGN

×

Proposed issue of securities - AGN

10 April 24

Patient Dosing Milestone Achieved in Phase 2 Stroke Trial

×

Patient Dosing Milestone Achieved in Phase 2 Stroke Trial

10 April 24

Trading Halt

×

Trading Halt

28 March 24

First Patient Dosed in Phase 2 Stroke Trial of ARG-007

×

First Patient Dosed in Phase 2 Stroke Trial of ARG-007

25 March 24

FDA Grants Rare Pediatric Disease Designation For HIE

×

FDA Grants Rare Pediatric Disease Designation For HIE

07 March 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

28 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

16 February 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

12 February 24

Phase 2 Manufacturing Completed & Trial Update

×

Phase 2 Manufacturing Completed & Trial Update

02 February 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

02 February 24

Cleansing Notice

×

Cleansing Notice

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

14 December 23

Phase 2 Stroke Clinical Trial Update

×

Phase 2 Stroke Clinical Trial Update

01 December 23

Results of Annual General Meeting

×

Results of Annual General Meeting

01 December 23

Amended Constitution

×

Amended Constitution

01 December 23

Final Director's Interest Notice

×

Final Director's Interest Notice

01 December 23

Initial Director's Interest Notice

×

Initial Director's Interest Notice

01 December 23

AGM Presentation

×

AGM Presentation

AGN Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.06 -0.06 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.06 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -171.2 -292.2 0.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 9.3 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 1.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.05 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -98.6 -305.3 -5.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -7.2 -10.6 -10.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 1.6 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.10 0.08 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.09 0.10 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39,250.2 2.1 -18.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 73 74 88 Lock Lock Lock
Basic m Lock Lock Lock Lock 73 74 88 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 1 4 7 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -1 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -245.5 -228.2 -52.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -1 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -245.5 -228.2 -52.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 -4 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -1 -4 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -168.5 -297.4 -17.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -3 -3 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 8 5 4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -1,679.0 -221.3 1.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 9 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 7 9 10 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -9 -9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 7 8 8 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 7 8 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37,116.6 21.3 -7.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -14.2 -45.2 -50.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.0 -49.2 -62.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -38.6 -57.4 -82.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -30.0 -54.0 -60.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -30.5 -44.4 -41.3 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -66,285.0 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 5.4 2.0 1.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -104.3 -107.3 -121.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.1 12.3 5.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.1 12.3 5.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.2 98.6 97.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -245.8 -456.8 -176.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -14.2 -45.2 -50.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.0 -49.2 -62.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -15.0 -49.2 -62.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

1.6%

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AGN Shortsell

Frequently Asked Questions

The current share price of Argenica Therapeutics Ltd (AGN:ASX) is AU$0.76.
The 52-week high share price for Argenica Therapeutics Ltd (AGN:ASX) is AU$0.77.
The 52-week low share price for Argenica Therapeutics Ltd (AGN:ASX)? is AU$0.29.
The current TTM dividend payout for Argenica Therapeutics Ltd (AGN:ASX) is 1.60.
Argenica Therapeutics Ltd (AGN:ASX) does not pay a dividend.
Argenica Therapeutics Ltd (AGN:ASX) has a franking level of 0.0%.
Argenica Therapeutics Ltd (AGN:ASX) is classified in the Healthcare.
The current P/E ratio for Argenica Therapeutics Ltd (AGN:ASX) is 9.30.